Champions Oncology Past Earnings Performance
Past criteria checks 0/6
Champions Oncology's earnings have been declining at an average annual rate of -46.2%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 10.7% per year.
Key information
-46.2%
Earnings growth rate
-44.2%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 10.7% |
Return on equity | -87.8% |
Net Margin | -1.1% |
Last Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Sentiment Still Eluding Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 10Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth
Oct 24It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)
Jun 14Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Revenue & Expenses Breakdown
How Champions Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Oct 24 | 54 | -1 | 17 | 7 |
31 Jul 24 | 52 | -3 | 18 | 8 |
30 Apr 24 | 50 | -7 | 18 | 10 |
31 Jan 24 | 49 | -10 | 18 | 10 |
31 Oct 23 | 50 | -10 | 18 | 11 |
31 Jul 23 | 53 | -8 | 18 | 11 |
30 Apr 23 | 54 | -5 | 17 | 12 |
31 Jan 23 | 54 | -3 | 17 | 11 |
31 Oct 22 | 54 | 0 | 16 | 10 |
31 Jul 22 | 52 | 0 | 16 | 10 |
30 Apr 22 | 49 | 1 | 15 | 9 |
31 Jan 22 | 47 | 0 | 14 | 9 |
31 Oct 21 | 44 | 0 | 14 | 9 |
31 Jul 21 | 43 | 0 | 13 | 8 |
30 Apr 21 | 41 | 0 | 12 | 7 |
31 Jan 21 | 39 | -1 | 12 | 7 |
31 Oct 20 | 37 | -2 | 12 | 6 |
31 Jul 20 | 35 | -1 | 11 | 6 |
30 Apr 20 | 32 | -2 | 11 | 6 |
31 Jan 20 | 31 | 0 | 10 | 5 |
31 Oct 19 | 29 | -1 | 9 | 5 |
31 Jul 19 | 28 | -1 | 8 | 5 |
30 Apr 19 | 27 | 0 | 8 | 5 |
31 Jan 19 | 24 | 0 | 7 | 5 |
31 Oct 18 | 23 | 0 | 7 | 4 |
31 Jul 18 | 21 | 0 | 6 | 4 |
30 Apr 18 | 20 | -1 | 7 | 4 |
31 Jan 18 | 19 | -3 | 7 | 4 |
31 Oct 17 | 18 | -5 | 7 | 4 |
31 Jul 17 | 17 | -5 | 8 | 4 |
30 Apr 17 | 15 | -7 | 8 | 4 |
31 Jan 17 | 15 | -7 | 8 | 4 |
31 Oct 16 | 14 | -8 | 8 | 4 |
31 Jul 16 | 12 | -10 | 9 | 4 |
30 Apr 16 | 11 | -10 | 9 | 4 |
31 Jan 16 | 12 | -12 | 9 | 4 |
31 Oct 15 | 11 | -12 | 9 | 4 |
31 Jul 15 | 10 | -13 | 9 | 5 |
30 Apr 15 | 9 | -13 | 10 | 5 |
31 Jan 15 | 8 | -12 | 10 | 4 |
31 Oct 14 | 10 | -10 | 11 | 4 |
31 Jul 14 | 10 | -9 | 10 | 3 |
30 Apr 14 | 12 | -7 | 9 | 2 |
31 Jan 14 | 11 | -7 | 8 | 2 |
Quality Earnings: CSBR is currently unprofitable.
Growing Profit Margin: CSBR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CSBR is unprofitable, and losses have increased over the past 5 years at a rate of 46.2% per year.
Accelerating Growth: Unable to compare CSBR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CSBR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: CSBR has a negative Return on Equity (-87.81%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 15:31 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/10/31 |
Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Champions Oncology, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Paul Bienstock | B. Riley Wealth |
Matthew Hewitt | Craig-Hallum Capital Group LLC |
Paul Knight | Janney Montgomery Scott LLC |